As of June 2026, the FDA's December 2024 Pharmacy Compounding Advisory Committee evaluation concluded that the criteria weighed against placing AOD-9604 (free base) or AOD-9604 acetate on the 503A Bulks List, and AOD-9604 is currently listed as Nominated but Withdrawn from FDA Category 2
Monitor for Results and Side Effects: Track changes in weight, body measurements, energy levels, and any adverse reactions
By keeping peptide production closer to home, we can better control product standards, reduce reliance on uncertain imported inventory, and provide Canadian researchers with a more transparent and reliable source for research peptides
discontinue if serious reactions occur
What the Science Says About Combining NAD+ and 5-Amino-1MQ While no large-scale human trials have been published yet on the combined use of NAD+ therapy and 5-Amino-1MQ, interest in this area continues to grow, particularly in the fields of metabolic health and longevity medicine
Slowing NNMT production may help prevent age-related muscle loss and promote muscle repair (having muscle is essential for maintaining a healthy metabolism and burning fat efficiently)
